Treace Medical Concepts (TMCI)

Treace is best known for Lapiplasty, a patented 3D bunion correction procedure. Traditional bunion surgery often focuses on shaving or shifting the visible bump near the big toe, while Treace’s approach is designed to correct the underlying three-dimensional deformity at the unstable joint in the midfoot. The procedure aims to address the root cause of the bunion, realign the metatarsal bone in multiple planes, and stabilize the correction with specialized instrumentation and implants.

The company’s product portfolio supports surgeons through a system-based approach that includes procedure-specific tools, fixation devices, and related technologies for bunion correction and adjacent midfoot procedures. Treace positions its platform around reproducibility, procedural efficiency, and the potential for patients to return to activity sooner than with some traditional approaches, depending on the clinical situation and physician guidance.

As a listed medical device company, Treace’s performance depends on surgeon adoption, procedure volumes, reimbursement dynamics, manufacturing execution, and continued expansion of its product ecosystem. Its focus is narrower than that of large diversified orthopedic companies, but that specialization gives it a distinct identity in the foot and ankle market. For investors, TMCI represents exposure to a targeted orthopedic category where innovation is centered on changing the surgical standard of care for bunion deformity.